Flow cytometry is widely used for cell identification and characterization and involves labelling biological and clinical samples with fluorochrome-conjugated antibodies specific to cell markers. This requires use of expensive exogenous reagents and necessitates complex pre-processing of samples. Additionally, extensive challenges arise in clinical samples consisting of highly plastic and heterogenous cell types observed in diseases such as cancer. As such, it is challenging to apply flow cytometry to point-of-care diagnostic applications. To address this issue, we investigated the combination of diffuse reflectance spectroscopy (DRS), microfluidics and machine learning to offer rapid, low-cost, label-free cell identification for potential deployment at the point of care. To achieve this, we utilized a compact fibre-optic diffuse reflectance spectrometer with multi-depth sensing capability. This system was applied to a proof-of-concept cell identification study where we were able to discriminate triple negative breast cancer cells from healthy fibroblasts using commercially available flow channel slides (Ibidi GmbH, channel dimensions: 5 mm width, 0.4 mm height). However, we observed high interexperimental variability, which was partially attributed to the relatively large fluidic channels. Thus, we investigated in-house fabrication of microfluidics of varying channel widths (0.6-2mm). To this end, we used a Mars ELEGOO 3D printer and commercially available printing materials to batch fabricate optically and mechanically viable microfluidic chips that were both cheap and customizable. Using these in-house microfluidic devices, we demonstrated DRS-based discrimination of cancer cells of different origins, further indicating the potential of this approach for point-of-care cell identification/characterization. Ultimately, we hope this work will lead to the development of cheap, deployable, and accurate point-of-care tools for rapid, label-free cell identification.
Environmental enteric dysfunction (EED) is a subclinical disorder of intestinal function common in tropical countries and settings of poverty and economic disadvantage. EED manifests during infancy and is associated with undernutrition, poor sanitation, and gut infections. EED is characterised by inflammation, reduced absorptive capacity, and reduced barrier function (i.e., increased permeability) in the small intestine. The precise mechanisms underlying changes in gut barrier function (and other aspects of intestinal function) in EED remain elusive. Furthermore, current diagnostic methods to assess gut permeability (e.g., endoscopic biopsies or permeability assays such as the Lactulose:Mannitol test) are invasive, unreliable and/or challenging to perform in infants and patients with other coexisting urological conditions. Consequently, there is an urgent need to develop diagnostic technologies that can non-invasively and affordably monitor intestinal permeability in low-resource settings where EED is prevalent.
To address this need, we present a prototype semi-wearable, wireless sensor for non-invasive assessment of intestinal permeability via transcutaneous fluorescence spectroscopy. The approach relies on the ingestion of a fluorescent contrast agent (fluorescein) and the subsequent detection of its permeation from the gut into the bloodstream using a wearable probe. We outline the development of the semi-wearable sensor and report preliminary in vivo deployment. This showcases the potential of transcutaneous fluorescence spectroscopy as a wearable and non-invasive diagnostic tool for assessing gut function in low-resource settings.
SignificanceThe integrity of the intestinal barrier is gaining recognition as a significant contributor to various pathophysiological conditions, including inflammatory bowel disease, celiac disease, environmental enteric dysfunction (EED), and malnutrition. EED, for example, manifests as complex structural and functional changes in the small intestine leading to increased intestinal permeability, inflammation, and reduced absorption of nutrients. Despite the importance of gut function, current techniques to assess intestinal permeability (such as endoscopic biopsies or dual sugar assays) are either highly invasive, unreliable, and/or difficult to perform in certain patient populations (e.g., infants).AimWe present a portable, optical sensor based on transcutaneous fluorescence spectroscopy to assess gut function (in particular, intestinal permeability) in a fast and noninvasive manner.ApproachParticipants receive an oral dose of a fluorescent contrast agent, and a wearable fiber-optic probe detects the permeation of the contrast agent from the gut into the blood stream by measuring the fluorescence intensity noninvasively at the fingertip. We characterized the performance of our compact optical sensor by comparing it against an existing benchtop spectroscopic system. In addition, we report results from a human study in healthy volunteers investigating the impact of skin tone and contrast agent dose on transcutaneous fluorescence signals.ResultsThe first study with eight healthy participants showed good correlation between our compact sensor and the existing benchtop spectroscopic system [correlation coefficient (r)>0.919, p<0.001]. Further experiments in 14 healthy participants revealed an approximately linear relationship between the ingested contrast agent dose and the collected signal intensity. Finally, a parallel study on the impact of different skin tones showed no significant differences in signal levels between participants with different skin tones (p>0.05).ConclusionsIn this paper, we demonstrate the potential of our compact transcutaneous fluorescence sensor for noninvasive monitoring of intestinal health.
Tumour hypoxia is a critical factor in treatment failure and resistance, and its accurate measurement with diffuse reflectance spectroscopy (DRS) could be used for prognostic and response monitoring purposes. In this in vivo characterisation study, we sequentially measured oxygenation trends over the entire course of tumour growth in mice using a multi-depth, fibre-optic DRS probe. Results demonstrated a clear downtrend in oxygenation over time. This progression was not always linear, with significant heterogeneity over time and between mice. Our findings will be further validated against gold standards prior to investigating whether hypoxia can be used to predict radiotherapy responses.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.